53 results about "With glomerular filtration rate" patented technology

The invention discloses a method and a system for constructing a renal function automatic estimation model based on plain-scan CT (Computed Tomography). The method comprises the following steps: S1, collecting image data of a patient suffering from renal atrophy or hydronephrosis; s2, training a kidney parenchyma and hydronephrosis region automatic segmentation model based on UNETR by using kidney parenchyma and hydronephrosis regions manually described by a radiologist; s3, image omics features are extracted from the images, and data are screened; s4, constructing a renal function index regression model, wherein the renal function index regression model comprises a GFR regression model and an SRF regression model; s5, verifying an estimated value of the regression model; and S6, calculating GFR and SRF by using the renal function index regression model, and distinguishing kidneys in different health states. By adopting the method, the glomerular filtration rate and the lateral renal function of each kidney can be automatically estimated. A rapid, convenient and low-cost renal function evaluation method is provided for treating patients with renal atrophy or hydronephrosis.

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

A method and system for constructing a glomerular filtration rate estimation model, including: step 1: performing mRMR feature selection on the original data set, screening out the independent variable features, and using the transformed data set as the basic data set for subsequent modeling; step 2: constructing two linear regression models on the basic data set; step 3: performing sampling with replacement on the basic data set, and removing duplicate samples; step 4: training the set model on the N sampled data sets after removing duplicates in step 3, and obtaining its parameters: obtaining N temporary local models, and performing multivariate linear regression modeling on the N sampled data sets after removing duplicates according to the above two forms obtained in step 2; step 5: constructing a global model, using the average of the local model parameters obtained in step 4 as the parameters of the global model, and the obtained global model is the constructed glomerular filtration rate estimation model. The present invention models data for a specific population and obtains a GFR estimation model that is more suitable for the specific population.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

Verdazil derivative compounds and compositions thereof, useful as contrast agents for biomedical imaging, are provided. The compounds and compositions of this disclosure can be used, for example, for quantitative and / or qualitative assessment of glomerular filtration rate (GFR) in subjects, providing a reliable and rapid assessment of renal function.

The invention discloses a prediction model of a glomerular filtration rate after cardio-pulmonary resuscitation, a construction method and application thereof. The method comprises the following steps: collecting and preprocessing sample data; determining an independent variable, a dependent variable and an end variable; screening independent influence factors, and evaluating a relationship between the independent influence factors based on a variance expansion factor; constructing a column graph prediction model based on the independent influence factors; performing accuracy evaluation on the prediction model based on the accuracy and the mean absolute error; performing calibration degree analysis on the prediction model through a calibration curve, Bland-Altman consistency evaluation and pairing T test; evaluating the prediction efficiency of the prediction model through an ROC curve and an AUC; and verifying the universality and extrapolation of the prediction model. The early prediction model of the glomerular filtration rate after cardio-pulmonary resuscitation is constructed, so that the probability of chronic kidney diseases can be predicted within 24 hours, early discovery and early intervention are realized, and the disease progress is delayed.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The present invention relates to a pharmaceutical composition for treating diabetic nephropathy, wherein the composition comprises a screened cobra cardiotoxin having a specific amino acid sequence. The diabetic nephropathy (DKD) refers to chronic kidney disease caused by diabetes. The composition can reduce the urine albumin / creatinine ratio (UACR) of diabetic nephropathy and improve the estimated glomerular filtration rate (eGFR).

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for preventing and treating hyperuricemia, which is prepared from the following raw materials by weight: 5-20g of gynostemma pentaphyllum, 10-20g of selaginella doederleinii hieron, 5-15g of berchemia lineate, 5-15g of parthenocissus parvifolia, 12-15g of lotus leaf, 12-15g of cassia seed, 12-15g of white paeony root and 3-6g of raw liquorice. The traditional Chinese medicine composition has no obvious influence on the normal blood sugar level, has stable hypoglycemic activity when being used by diabetes patients, cannot reduce the normal blood sugar state when being taken, can reduce the uric acid level, protect the kidney, improve the glomerular filtration rate and promote uric acid excretion, and can effectively treat, inhibit or prevent hyperuricemia.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The invention provides an SPECT / CT-based renal function determination method and device and a processing system, designs a novel renal function determination architecture, and combines a CT structure image to more accurately distinguish kidney tissues and perirenal tissues and extract more real double-kidney signals compared with a traditional scheme that SPECT images are used for sketching double-kidney ROI (Region of Interest). The high time resolution and the high spatial resolution are both considered, so that the time radioactivity curve and the glomerular filtration rate of the separated kidney can be accurately measured, the high-quality measurement requirement for the separated kidney function in clinical work is met, and high-quality diagnosis and treatment service can be provided for a patient.

This disclosure is directed to devices, systems, and techniques for estimating a serum potassium level. An example system includes a plurality of electrodes, sensing circuitry configured to sense an ECG of a patient, and processing circuitry. The processing circuitry is configured to determine a T-wave morphology in the ECG and based on the T-wave morphology, determine an estimate of serum potassium in blood of the patient. The processing circuitry is configured to determine that the estimate of serum potassium in the blood satisfies a threshold and based on the estimate of serum potassium in the blood satisfying the threshold, generate an indication for output that is based at least in part on the estimate of serum potassium in the blood satisfying the threshold.

The invention discloses application of disulfiram in preparation of a medicine for treating UMOD gene mutation type autosomal dominant renal tubulointerstitial nephropathy, and belongs to the field of biomedicine. The application comprises the application of the disulfiram in preparation of the medicine for treating the hereditary tubulointerstitial nephropathy. According to the invention, a new pathogenic mutation UMOD c.106Cgt is identified; according to the invention, the pathogenicity of the gene is verified through a UMODH36Y mouse model constructed by CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated 9). DSF intervention is adopted, the serum creatinine and glomerular filtration rate (tGFR) of mice can be remarkably improved, and renal interstitial inflammation and fibrosis are relieved. The discovery prompts that the DSF realizes the therapeutic effect of renal function protection-inflammation inhibition-fibrosis relief in an ADTKD-UMOD animal model through targeted regulation of a pyroptosis pathway, a novel therapeutic strategy is provided for ADTKD-UMOD, and the clinical transformation period can be remarkably shortened due to the characteristic of new use of old medicines. The discovery lays an experimental foundation for developing a precise treatment scheme for the hereditary renal tubulointerstitial disease.

The application belongs to the technical field of disease prognosis, and particularly relates to a marker for predicting the prognosis risk of an acute coronary syndrome patient and a system for predicting the prognosis risk. The application provides a marker for predicting the prognosis risk of an acute coronary syndrome patient, which comprises a biomarker and a chronic kidney disease index; the biomarker comprises NT-proBNP and RBP4; and the chronic kidney disease index is an eGFR index. The application also provides a system for predicting the prognosis risk of an acute coronary syndrome patient, which comprises a protein detection module, a chronic kidney disease index detection module, a prognosis score determination module and a prognosis risk evaluation module. The system for predicting the prognosis risk of the application effectively solves the technical problems that the existing GRACE score prognosis prediction method has low prediction accuracy in the East Asian population and has limited prediction value for long-term cardiovascular adverse event risks of more than 1 year.

The invention relates to the technical field of nephropathy prediction, and discloses an NLR-based IgA nephropathy treatment effect prediction method, which comprises the following steps: collecting index factors of a patient; the index factors comprise an NLR value, a serum creatinine level, a uric acid level and a glomerular filtration rate; the index factors are preprocessed; screening a reserved index factor according to a first threshold value, constructing a final index change rate interval according to a second threshold value and the index change rate interval, screening out a final data set according to the final index change rate interval, obtaining the index factor of the patient in real time, inputting the trained prediction model, and outputting the response of the patient to glucocorticoid treatment; on the basis of the existing NLR, the serum creatinine level, the uric acid level and the glomerular filtration rate which have significant influence on the glucocorticoid treatment response and index data in a specific range are screened as a training set, and the prediction result of the subsequent patient on the glucocorticoid treatment response through the model trained by the training set is more accurate.

This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The present invention relates to a method for measuring glomerular filtration rate (GFR) ex vivo in a subject that has been administered a contrast agent and that has been subjected to computed tomography (CT) or magnetic resonance imaging (MRI) including an excretion phase, a plain scan phase, an arterial phase, and a renal parenchyma phase or a portal vein phase, the method includes the step of calculating contrast agent clearance from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

The invention discloses a device and equipment for predicting the death risk of a sepsis shock patient after hematopoietic stem cell transplantation and a storage medium. The invention further discloses a CARPET integral model for predicting the death risk of the sepsis shock patient after hematopoietic stem cell transplantation and a method for predicting the death risk of the sepsis shock patient after hematopoietic stem cell transplantation based on the CARPET integral model. According to the method, the death risk of a sepsis shock patient within 28 after hematopoietic stem cell transplantation can be predicted by measuring the albumin content, bilirubin content, PaO2 / FiO2, lactic acid content and glomerular filtration rate of the sepsis shock patient after hematopoietic stem cell transplantation and combining sepsis shock time. Compared with an SOFA scoring model, a calibration curve between 28-day death rates predicted and observed by the CARPET integral model shows better consistency, and DCA analysis shows that the clinical benefits of patients are more.

The present invention discloses a Chinese medicine composition for treating chronic kidney disease and its application. The Chinese medicine composition comprises 30-50 parts of astragalus, 2-10 parts of leech, 50-70 parts of radix scutellariae, 5-20 parts of seaweed and 5-20 parts of turtle shell. The Chinese medicine composition can be used to prepare a preparation for treating chronic kidney disease. The Chinese medicine composition has a good therapeutic effect on the decrease of glomerular filtration rate and deterioration of renal function caused by chronic kidney disease, especially the increase of creatinine, and can significantly improve the clinical symptoms of patients with chronic kidney disease; it has no obvious damage to liver function and coagulation function, has high safety, and has broad application prospects in the field of chronic kidney disease treatment.

The invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine compound for treating chronic kidney disease, the traditional Chinese medicine compound is composed of 20-40 parts of raw rhubarb, 30-60 parts of calcined oyster, 20-40 parts of red sage root, 20-40 parts of dandelion, 15-30 parts of Chinese starjasmine stem, and 15-30 parts of serissa serissoide, the calcined oyster is prepared by calcining oyster shell and crushing the calcined oyster shell into 100-200 mesh fine powder, and the medicine is administered through rectal perfusion. The traditional Chinese medicine composition is taken twice a day, is reserved for 30-60 minutes each time, and can reduce serum creatinine and urea nitrogen levels, improve the glomerular filtration rate and protect the renal function. The raw rhubarb, the calcined oyster shell, the red sage root, the dandelion, the Chinese starjasmine stem and the serissa serissoide are scientifically matched to achieve a synergistic effect. The raw rhubarb has the effects of relaxing bowels and discharging turbidity, the calcined oyster adsorbs toxin, the salvia miltiorrhiza has the effects of promoting blood circulation and removing blood stasis, the dandelion has the effects of clearing away heat and toxic materials, the Chinese starjasmine stem has the effects of dispelling wind and dredging collaterals, and the serissa serissoide has the effects of promoting diuresis and descending turbidity, so that a multi-target treatment system of activating blood, detoxifying, discharging

The invention discloses a multi-database data management method and system for IgA nephropathy treatment, and relates to the technical field of data management. According to the method, multi-source clinical data is collected, a structured data set is formed based on data quality scoring and conflict resolution, the disease course stage of a patient is dynamically recognized based on a biomarker and a glomerular filtration rate, and differentiated collection, storage, synchronization and access strategies based on the disease course stage of the patient are specifically generated; multi-database collaborative management is executed, and the management effect is iteratively optimized through the data collection integrity rate, the data synchronization timeliness rate, the storage resource utilization rate and the response time; the problem that the IgA nephropathy multi-source database management and synergy efficiency is low is effectively solved, and the accuracy and efficiency of IgA nephropathy multi-source data management are remarkably improved.

The invention provides a glomerular filtration rate estimation method and device for a patient with asymmetric double renal functions. The method comprises the following steps: acquiring basic information, clinical data, laboratory detection data and iconography data of a patient, wherein the iconography data comprises kidney volume, blood flow volume, cortex and medullary thickness and kidney function expression of the right kidney and the left kidney; by analyzing iconography data, a functional difference measurement coefficient for quantifying the asymmetry of double kidney functions is calculated. Thirdly, extracting a global feature vector of the patient by using a deep learning model, and performing fusion processing on the iconography data, the clinical data and the laboratory detection data to generate a comprehensive feature vector; and on the basis, the functional weights of the right kidney and the left kidney are adjusted according to the functional difference measurement coefficient, finally, the adjusted functional weights and the global feature vectors are input into a deep regression model, and a corrected GFR estimated value is obtained through calculation. And more accurate renal function evaluation can be provided according to the condition that double renal functions are asymmetric.

Systems, devices, and methods involve approaches for determining a calibration value for an individual, estimating a creatinine level using a chemical sensor (e.g., based on an optical property of a chemical sensor), and estimating a glomerular filtration rate (GFR) based, at least in part, on the calibration value and the creatinine level.

The invention relates to the technical field of medical care informatics, and discloses an osteoporosis prevention strategy analysis method and system, and the method comprises the steps: a discrete event sequence extraction module extracts clinical events from an electronic medical record; the parameter adaptive mapping module constructs a time scale scaling factor by using the glomerular filtration rate, performs reverse correction on the attenuation parameter of the risk pulse function, and determines positive correlation mapping of the attenuation rate and the clearing efficiency; the time domain overlay analysis module calculates an instantaneous bone loss index and generates a bone mineral density evolution trajectory; according to the method, physiological metabolism indexes are converted into time control variables of a mathematical model, dynamic distortion caused by individual metabolism differences is avoided, and quantification and early warning of the risk long-tail superposition effect in the body of a patient with metabolic hypofunction are achieved.

The present invention relates to a method and a pharmaceutical composition for treating chronic kidney disease. The method and the pharmaceutical composition of the present invention relate to the combined use of doxazosin, pramipexole and metoprolol (or a pharmaceutically acceptable salt thereof), which can significantly improve chronic kidney disease, significantly reduce the urinary albumin excretion rate UACR, significantly improve the estimated glomerular filtration rate eGFR, and effectively delay the progression of renal function decline to end-stage renal failure.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for treating chronic kidney disease and its application. Its main active ingredients, by weight, include: Astragalus membranaceus 20-35 parts, Cuscuta chinensis 10-25 parts, Codonopsis pilosula 10-25 parts, Atractylodes macrocephala 10-20 parts, Poria cocos 10-25 parts, Dioscorea opposita 10-25 parts, Salvia miltiorrhiza 10-25 parts, and Coix lacryma-jobi 10-30 parts. Real-world cohort studies have shown that this traditional Chinese medicine composition for treating chronic kidney disease can significantly improve the survival rate of patients with chronic kidney disease, delay the decline in glomerular filtration rate, effectively reduce the risk of kidney disease progression, and has good safety.

A method, system, and medium for dynamically controlling infusion drip rate based on patient physiological parameters include: acquiring real-time physiological parameter data, medical history data, and drug attribute data of the patient; real-time physiological parameter data including glomerular filtration rate and B-type natriuretic peptide concentration; obtaining a safe drip rate range based on one or more of the real-time physiological parameter data, medical history data, and drug attribute data according to a preset rule base; calculating a recommended drip rate based on a machine learning model and a standard drip rate; obtaining a preset drip rate threshold range, and generating and outputting a first drip rate control command based on the recommended drip rate, the safe drip rate range, and the preset drip rate threshold range; monitoring the actual drip rate in real time and calculating the error value between the actual drip rate and the recommended drip rate; and dynamically adjusting the first drip rate control command based on the error value using a closed-loop control algorithm to generate and output a second drip rate control command.

Methods, systems, and apparatus for determining glomerular filtration rate (GFR) by acquiring a measurement dataset. Furthermore, this disclosure includes: acquiring a measurement dataset comprising multiple measurement entries acquired before and after administration of an exogenous fluorescent agent; generating an intrinsic fluorescence (IF) signal, the IF signal representing the detected fluorescence intensity emitted from the exogenous fluorescent agent within a diffuse reflective medium; determining whether the IF signal includes a portion of early fluorescence data; after determining this portion of the early fluorescence data, identifying an operable IF signal range by filtering the IF signal associated with the early fluorescence data; determining a GFR value in the patient based on the rate of change of the operable IF signal; and providing the GFR value.